Best Practices for IO in Bladder Cancer

Nursing standard: Best practices for counselling and managing adverse events in patients with bladder cancer treated with immuno-oncology agents

 
Increasing enthusiasm has emerged within the oncology community with the availability of immune checkpoint inhibitors. Although considered to have good tolerability relative to traditional chemotherapy, use of checkpoint inhibitors is associated with a different spectrum of toxicities, termed immune-mediated adverse events (imAEs). The integration of immuno-oncology (IO) agents into cancer care may present certain challenges. This document provides oncology nurses with knowledge and tools to identify and manage imAEs in patients with bladder cancer treated with IO agents.

English Version
French Version

This program has been endorsed by CANO/ACIO through our Endorsement Policy.

Click here to learn how you can have your education program or material endorsed by us. 

 

Last Updated: March 12, 2019

Have feedback about our updated site? Let us know here 

© 2017 Canadian Association of Nurses in Oncology (CANO). All rights reserved.